Search

MANUFACTURE ASSOCIATE I - PROTEIN PURIFICATION/CONJUGATION - ASPYRIAN THERAPEUTICS, INC - SAN DIEGO, CA

Quickly expanding the team to support late stage pivotal clinical development. For research and development efforts...From Aspyrian...

 
 
 
Extending Nephron Development In Preterm Babies May Prevent Kidney Disease Later

EXTENDING NEPHRON DEVELOPMENT IN PRETERM BABIES MAY PREVENT KIDNEY DISEASE LATER

Scientists identify a possible therapeutic target to extend kidney development in preterm babies that would reduce the risk of kidney...

IMMUSANT GOES ON HIRING SPREE AHEAD OF PHASE 2 CELIAC VACCINE TRIAL

ImmusanT is boosting its senior staff, bringing on Daiichi Sankyo's SVP for internal medicine therapeutics, Ken Truitt, as its new...

 
 
 

NABRIVA LINES UP FDA FILING AFTER ANTIBIOTIC CLEARS SECOND PIVOTAL TEST

A second phase 3 trial of Nabriva Therapeutics' lefamulin has hit its primary endpoint. The positive readout further burnishes the...

ALLERGY THERAPEUTICS SHOWS DOSE RESPONSE IN MIDPHASE TRIAL, SETTING STAGE FOR PIVOTAL PROGRAM

A phase 2 trial of Allergy Therapeutics' grass pollen candidate met its primary endpoint of showing a dose-response relationship. With...

 
 
 
 
 
 
 
 
 
Celsius Snags $65M to Harness Single-Cell Genomics for Drug Discovery

CELSIUS SNAGS $65M TO HARNESS SINGLE-CELL GENOMICS FOR DRUG DISCOVERY

With biotech flush with venture capital funding, it seems that every hot new area of biology research now comes with its own startup....

 
 
 
A startup that wants to make treatments that edit single letters in our DNA just raised $87 million

A STARTUP THAT WANTS TO MAKE TREATMENTS THAT EDIT SINGLE LETTERS IN OUR DNA JUST RAISED $87 MILLION

Beam Therapeutics, a new startup co-founded by gene-editing pioneers, just raised $87 million to get its technology that changes single...

BIOSYNTHESIS OF ANGELYL-COA IN SACCHAROMYCES CEREVISIAE

The angelic acid moiety represents an essential modification in many biologically active products. These products are commonly known...

 
 
 
Evelo IPO Raises $85M for Microbiome Drugs in Inflammation, Cancer

EVELO IPO RAISES $85M FOR MICROBIOME DRUGS IN INFLAMMATION, CANCER

Evelo Biosciences now has $85 million to spend on its pipeline of drugs that target the human microbiome. The Cambridge, MA-based biotech...

 
 
 
New Approach for Treating Neuropathic Pain Discovered

NEW APPROACH FOR TREATING NEUROPATHIC PAIN DISCOVERED

Novel therapeutic that appears to interrupt the signaling cascades in the body required for multiple forms of neuropathic pain identified.